SCHEMBL7182500

SCHEMBL7182500

COc1cc(OC)c(C(=O)P(=O)(C(=O)c2c(Cl)c(Cl)c(Cl)c(Cl)c2Cl)c2ccccc2)c(OC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.41
CYP3A4 P08684 2/20 0.41
MAPT P10636 2/20 0.41
TP53 P04637 1/20 0.41
ATM Q13315 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ABCG2 Q9UNQ0 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
USP2 O75604 1/20 0.39
MAPK1 P28482 1/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
MEN1 O00255 2/20 0.39
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
PTPN1 P18031 1/20 0.38
POLB P06746 1/20 0.37
HTT P42858 1/20 0.37
CASP3 P42574 2/20 0.36
SENP8 Q96LD8 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7178118 0.92 ABCG2 (0.42) KMT2ACYP3A4MAPTTP53ATM
SCHEMBL2768729 0.92 KMT2A (0.47) KMT2ACYP3A4MAPTTP53ATM
SCHEMBL7180921 0.89 ABCG2 (0.41) KMT2ACYP3A4MAPTTP53ATM
SCHEMBL7175458 0.88 ABCG2 (0.46) KMT2ACYP3A4MAPTTP53ATM
SCHEMBL7189125 0.88 CA12 (0.47) KMT2AATMSMN1; SMN2MEN1HTT
SCHEMBL7188964 0.88 MAPT (0.48) KMT2ACYP3A4MAPTTP53ATM
SCHEMBL7184054 0.87 ABCG2 (0.42) KMT2ACYP3A4MAPTTP53ATM
SCHEMBL7175523 0.86 KMT2A (0.43) KMT2ACYP3A4MAPTTP53ATM
SCHEMBL7174597 0.86 ABCG2 (0.41) KMT2ACYP3A4MAPTTP53ATM
SCHEMBL7175981 0.86 ABCG2 (0.44) KMT2ACYP3A4MAPTTP53ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KMT2A 1586/4885CYP3A4 1652/4885MAPT 4870/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KMT2A 956/4885CYP3A4 1881/4885MAPT 4859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.